The impact on malaria of biannual treatment with azithromycin in children age less than 5 years: a prospective study

Table 3 Proportion of children with RDT positivity and clinical malaria at each visit by randomization arm

Outcome	Arm	Baseline		6 months		12 months		18 months		24 months		Overall p-value^#
Outcome	Arm	N	n (%)	N	n (%)	N	n (%)	N	n (%)	N	n (%)	Overall p-value^#
RDT+	Placebo	375	58 (15.5)	294	27 (9.8)	237	44 (18.6)	232	10 (4.3)	243	16 (6.6)	< 0.01
	Azithromycin	359	63 (17.6)	288	55 (19.3)	263	57 (21.7)	253	50 (19.8)	266	35 (13.2)
	p-value*	0.76		0.19		0.66		0.046		0.34
Clinical malaria	Placebo	375	16 (4.3)	294	8 (2.7)	237	16 (6.8)	232	4 (1.7)	243	3 (1.2)	0.16
	Azithromycin	359	22 (6.1)	288	15 (5.2)	263	16 (6.1)	253	6 (2.4)	266	5 (1.9)
	p-value*	0.56		0.29		0.83		0.61		0.66

RDT rapid diagnostic test for malaria
*Test for cross-sectional association using Generalized Estimating Equation approach to test for differences while accounting for clustering at the community level
^#Test for differences across the five visits using test for repeated measures

ISSN: 1475-2875